Interactions

Globocan 2000. Int J Cancer. 2001;94(2):153-156.

2. Instituto Nacional do Câncer [Página da internet]. Rio de Janeiro: Ministério da Saúde; c1996-2008. [uptated 2008 maio; acesso em 20 de junho de 2008]. Disponível em http://www.inca.gov.br.

3. Greene, FL et al. Manual do Estadiamento do Câncer. 6a ed. Porto Alegre: Artmed; 2004.

4. Shih A, Miaskowski C, Dodd MJ, Stotts NA, Macphail L. A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncology Nursing Forum. 2002;29(7):1063-1078.

5. Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ. Complications of radiation therapy for head and neck cancers. Cancer Nursing. 2002;25(6):461- 467.

6. Hoffman HT, karnell LH, Funk GF, Robinson RA, Menck HR. The national cancer data base report on cancer of the head and neck. Arch Otolaryngol. Head Neck Surg. 1998;124(9):951-962.

7. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CG, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66(3):253-262.

8. Fu KK. Combined-modality therapy for head and neck cancer. Oncology. 1997; 11(2):1781-1790.

9. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck câncer? Radiother Oncol. 1999;52(2):157-164.

10. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003 Nov 27;349(22):2091-8.

11. Nguyen NP, Moltz CC , Frank C, Vos P, Smith HJ, Karlsson U, et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Annals of Oncology. 2004;15(3):383-388.

12. Symonds RP, Mcilroy P, Khorrami J, Paul J, Puper E, Alcock SR, et al. The reduction of radiation mucositis by selective decontamination antibioctic pastilles: a placebo-controlled double-blind trial. Br J Cancer. 1996;74(2):312-317.

13. Parulekar W, Mackenzie R, Bjarnason G, Jordan RCK. Scoring oral mucositis. Oral Oncology. 1998; 34(1):63-71.

14. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004; 100(9):1995-2025.

15. Lockhart PB, Sonis ST. Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J Dermatol Surg Oncol. 1981;7(12):1019-1025.

16. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J. Radition Oncology Biol. Phys 2000;47(1):13-47.

17. Saad ED, Hoff PM, Carnelós RP, Katz A, Novis YAS, Pietrocola M, et al. Critérios comuns de toxicidade do Instituto Nacional de Câncer dos Estados Unidos. Ver. Bras. Cancerol. 2002;48(10):63-96.

18. Porock D, Nikoletti S, Cameron F. The relationship between factors that impair wound healing and the severity of acute radiation skin and mucosal toxicities in head and neck cancer. Cancer Nursing. 2004;27(1):71-78.

19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of cancer (EORTC). Int J Radiation Oncology Biol Phys. 1995;31(5):1341-1346.

20. Denham JW, Walker QJ, Lamb DS, Hamilton CS, O'brien PC, Spry NA et al. Mucosal regeneration during radiotherapy. Radiother Oncol. 1996;41(2):109-18. 21. Browman GP, Wong G, Hodson I, Sathya J, Russeli R, Mcalpine L, et al. Influence

of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328(3):159-163.

22. Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol. 1990;63(751): 554-556.

23. Bernier J, Thames HD, Smith CD, Horiot JC. Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radiother Oncol. 1998;47(2):137-43.

24. Baker DG. The radiobiological basis for tissue reactions in the oral cavity following therapeutic x-irradiation. A review. Arch Otolaryngol. 1982;108(1): 21-4.

25. Lionel D, Christophe L, Marc A, Jean-Luc C. Oral mucositis induced by anticancer treatments: physiopathology and treatments. Ther Clin Risk Manag. 2006;2(2):159- 68.

26. Naidu MUR, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy- induced and/or therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia. 2004;6(5):423-431.

27. Vera-Lionch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radition treatment for head and neck carcinoma. Cancer 2006;106(2):329-336.

28. Mose S, Adamietz IA, Saran F, Thilmann C, Heyd R, Knecht R, et al. Can Prophylactic Application of immunoglobulin decrease radiotherapy-induced oral mucositis? Am J Clin Oncol. 1997;20(4):407-411.

29. Rubenstein EB, Peterson DE, Schubert M, Keefe D, Mcguire D, Epstein J, et al. Clinical practive guidelines for the prevention and treatment of cancer therapy- induced oral and gastrointestinal mucositis. Cancer. 2004;100(9Suppl):2026-2046.

30. Des Rochers C, Dische S, Saunders MI. The Problem of cigarette smoking in radiotherapy for cancer in the head and neck. Clinical Oncology (R Coll Radiol). 1992;4(4):214-6.

31. Sonis ST, Costa JW JR, Evitts SM, Lindquist LE, Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1992;74(6):749-755.

32. Navajesh M. Xerostomia-diagnosis and treatment. Am J Otolaryngol 1983;4(4):283- 292.

33. Bez C, Demarosi F, Sardella A, Lodi G, Bertolli VG, Annaloro C, et al. GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(3):311-5.

34. Ryu JK, Swann S, Leveque F, Scarantino CW, Johnson D, Chen A, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys. 2007;67(3):643-50.

35. Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys. 1991;20(1):147-52.

36. Henke M, Bechtold C, Momm F, Dorr W, Guttenberger R. Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radition Oncology Biol Phys. 2000;48(2):339-345.

37. Mantini G, Manfrida S, Francesco C, Giammarino D, Petrone A, Vitucci P, et al. Impacto f dose and volume on radiation-induced mucositis. Rays 2005; 30(2):137- 144.

38. Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART Trial. Radiother Oncol. 2001;60(2):123-35.

39. Lichtman, SM. Physiological Aspects of Aging. Implications for the treatment of cancer. Drug&Aging. 1995; 7(3):212-225.

40. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2(12):1404-13.

41. Ikebe T, Seki K, Nakamura S, Takenoshita Y, Nakayama H, Shinohara M, et al. Severity of oral mucositis correlates with the response of oral cancer to preoperative radiochemotherapy. Int J Oral Maxillofac Surg. 2005;34(6):642-5.

42. Albuquerque ILS, Camargo TC, Prevenção e tratamento da mucosite oral induzida por radioterapia:revisão de literatura. Rev Bras Cancerol. 2007;53(2):195-209. 43. Dodd MJ, Miaskowski C, Dibble SL, Paul SM, Macpbail L, Dreenspan D, et al.

Factors influencing oral mucositis in patients receiving chemotherapy. Cancer Practive. 2000;8(6):291-297.

44. Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. European Journal of Cancer Care. 2002;11(1):33-43.

45. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1-12.

46. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J. Radition Oncology Biol Phys. 2007;68(4):1110-1120.

47. Aziz L, Ebenfelt A. Mucosal secretion changes during radiotherapy in the oral cavity. Clin Oral Investig. 2007;11(3):293-6.

48. Mccarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in câncer patients receiving 5-fluorouracil. Oral Oncology. 1998; 34(6):484-490.

49. Raber-Durlacher JE. Current practices for management of oral mucositis in câncer patients. Support Care Cancer. 1999;7(2):71-74.

50. Blot WJ, Mclaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1998;48(11):3282-7.

51. Carvalho MB, Lenzi J, Lehn CN, Fava CN, Amar A, Kanda JL, et al. Características clínico-epidemiológicas do carcinoma epidermóide de cavidade oral no sexo feminino. Rev Assoc Med Bras. 2001;47(3):208-214.

52. Dedivitis RA, França CM, Mafra AC, Guimarães FT, Guimarães AV. Caractrísticas clínico-epidemiológicas no carcinoma espinocelular de boca e orofaringe. Rev Bras Otorrinolaringol. 2004;70(1):35-40.

53. Mccollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94(15):1160-1167

54. Anthony L, Bowen J, Garden A, Sonis S. New thoughts on the pathobiology of regimen-related mucosal injury. Support care cancer. 2006;14(6):516-518.

55. Barasch A, Peterson D. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncology. 2003;39(2):91-100.

56. Gustke CJ, Stein SH, Hart TC, Hoffman WH, Hanes PJ, Russell CM, et al. HLA- DR alleles are associated with IDDM, but not with impaired neutrophil chemotaxis in IDDM. J Dent Res. 1998;77(7):1497-1503.

57. Ryan ME, Camu O, Kamer A. The influence of diabetes on the periodontal tissues. J Am Dent Assoc. 2003;134 Spec:30S-40S.

58. Schmidt AM, Weidman E, Lalla E, Yan SD, Hori O, Cao R, et al. Advanced glycation endproducts (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with diabetes. J Periodontal Res. 1996;31(7):508-515.

59. Soell M, Hassan M, Miliauskaite A, Haikel Y, Selimovic D. The oral cavity of elderly patients in diabetes. Diabetes&Metabolism. 2007;33(Suppl 1):10-18.

60. Turesson I, Nyman J, Holmberg E, Odén A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J. Radition Oncology Biol Phys. 1996; 36(5):1065-1075.

61. Shoen, FL. Os vasos sanguíneos. In: Kumar V, Abbas AK, Fausto N. Patologia - Bases patológicas das doenças. 7a ed. Traduzido por Zacharias MC. Rio de Janeiro: Elsevier; 2005. p.552-56.

Abstract

Objectives: Classify the level of oral mucositis according to the international CTC

parameters in head and neck tumor patients undergoing simultaneous radio and chemotherapy, and verify in our population whether or not the individual’s habits, tumor characteristics and treatment protocol have a role in the mucositis’ intensity. Methods: Fifty patients were enrolled, 45 male and 5 female; 39 white and 11afro-brazilians; 43 to 72 years old. Concerning to the primary tumor location, 32 patients were diagnosed with oropharynx tumor, 10 with oral cavity tumor, 3 with larynx tumor, 4 presented hipopharynx tumor and 1 with maxilla sinus tumor. Patients undergone megavoltage radiotherapy with doses in a range of 66 to 70Gy and an association of cisplatin and carboplatin chemotherapy concomitantly. Twenty six patients were submitted to previous surgery. All patients were interviewed by a nurse and asked about personal information and habits prior treatment. The level of mucositis was evaluated once a week until the end of the treatment. Results: 16% of patients presented mucositis grade III; 38% grade II; 30% grade I and 16% did not present any mucosa alteration. It was observed that 100% of the diabetic patients presented mucositis grade III.

Conclusions: Patient’s characteristics such as age, gender, race, smoking habit and high blood pressure, and clinical characteristics such as primary tumor location and stage of disease did not influence the severity of mucositis. Data showed that diabetes influences significantly the severity of mucositis in head and neck tumor patients undergoing chemo and radiotherapy concomitant.

Bibliografia consultada

Levin, J. Estatística – Aplicada a ciências humanas. 2a ed. São Paulo: Harbra; 1987. Rother ET, Braga MER. Como elaborar sua tese: estrutura e referências. 2a ed. rev. e atual. São Paulo: Amélia Gasparini; 2005.